Toronto, Ontario, November 8, 2021 – Clearmind Medicine Inc. (CSE: CMND, FSE:CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under treated health problems, announced today its participation at the Wonderland MiamiConference organized by Microdose.
Wonderland Miami Conference is the largest in-person conference in the psychedelic medicine industry. The conference will take place on November 8th and 9th at the Adrienne Arsht Center for Performing Arts in Miami. The conference will offer a unique in-person convergence of business, science, music, and emerging technologies.
Wonderland Miami by Microdose is also a thought-leadership platform and an opportunity to connect with influential leaders in science, policy, and business.
The speakers list includes Drs. Matthew Johnson, Robin Carhart-Harris, and Rick Doblin. Other featured speakers at the event include Mike Tyson, former professional boxer and undisputed heavyweight champion, who has advocated for the use of psychedelic drugs, as well as Lamar Odom, a two-time NBA Champion andOlympic Gold Medalist.
Clearmind Medicine team will introduce the company at the conference. To arrange a meeting, please contact: email@example.com
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
TheCompany’s intellectual portfolio currently consists of two patent families. The first, "Binge Behavior Regulators," has been granted in the U.S.,Europe, China and India, with pending divisional applications in Europe and theU.S. The second, “Alcohol Beverage Substitute,” has been approved for aEuropean patent, with pending applications in the U.S., China and India. TheCompany intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information, please contact:
Telephone: (778) 400-5347
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements.Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation ServicesProvider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.